You are here

IN THE THREE DAY PERIOD AFTER ONSET OF SYMPTOMS, SERIAL DETERMINATIONS OF BLOOD SERUM CPK AND LDH ISOENZYMES REMAIN THE BEST LABORATORY AID FOR EARLY DIAGNOSIS OF ACUTE MYO- CARDIAL INFARCTION.

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 4983
Amount: $50,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1986
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
470 Main Road
Towaco, NJ 07082
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 LESLIE OPPENHEIMER
 PRINCIPAL INVESTIGATOR
 () -
Business Contact
Phone: () -
Research Institution
N/A
Abstract

IN THE THREE DAY PERIOD AFTER ONSET OF SYMPTOMS, SERIAL DETERMINATIONS OF BLOOD SERUM CPK AND LDH ISOENZYMES REMAIN THE BEST LABORATORY AID FOR EARLY DIAGNOSIS OF ACUTE MYO- CARDIAL INFARCTION. THE PHASE I GOAL IS TO DEVELOP A RAPID,COST-EFFECTIVE, HIGH-PRECISION, DIAGNOSTIC ISOENZYME TEST UTILIZING HABER'S ADVANCED SEPARATION TECHNOLOGY, ELECTRO- MOLECULAR PROPULSION (EMP). IN THIS STUDY, DIFFERENT EMP MEDIA WILL BE EXAMINED FOR THEIR ABILITY TO SEPARATE CPK ANDLDH ISOENZYMES. ALSO, METHODS WILL BE DEVELOPED FOR THEIR RAPID DETECTION AND QUANTITATION. DURING PHASE II, HABER PROPOSES TO FURTHER IMPROVE AND DEVELOP THE METHODOLOGY AND TO PROTOTYPE A DIAGNOSTIC TEST FOR USE IN THE CLINICAL LABORATORY. HABER, WITH ITS ADVANCED EMP SEPARATION TECH- NOLOGY, ANTICIPATES THAT IT WILL DEVELOP A DIAGNOSTIC TEST FOR THESE ISOENZYMES WHICH WILL REQUIRE MINIMAL TECHNICAL HANDLING AND EXPERTISE AND WILL BE MORE ECONOMICAL THAN CURRENTLY USED LABORATORY TECHNIQUES.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government